期刊
JOURNAL OF MATERIALS CHEMISTRY B
卷 10, 期 37, 页码 7491-7511出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d2tb00592a
关键词
-
资金
- Imperial College London
- JSPS Overseas Research Fellowships [202160429]
CAR-T cell therapy has shown remarkable efficacy against hematological malignancies, but often leads to cytokine release syndrome. New approaches are being developed to control cytokine production and reduce the risk of this adverse event.
Chimeric antigen receptor (CAR) T cells have demonstrated remarkable anti-tumor efficacy against hematological malignancies, such as leukemia and lymphoma. However, patients treated with CAR-T cells frequently experience cytokine release syndrome (CRS), one of the most life-threatening adverse events of the therapy induced by systemic concentrations of pro-inflammatory cytokines throughout the body. Immunosuppressants such as tocilizumab are currently administered to treat the onset and progression of CRS symptoms. In order to reduce the risk of CRS, newly designed next-generation CAR-T treatments are being developed for both hematopoietic malignancies and solid tumors. In this review, we discuss six classes of interesting approaches that control cytokine production of CAR-T cell therapy: adaptor-based strategies, orthogonal cytokine-receptor pairs, regulation of macrophage cytokine activity, autonomous neutralization of key cytokines, kill switches and methods of reversible suppression of CARs. With these strategies, future CAR-T cell therapies will be designed to preemptively inhibit CRS, minimize the patients' suffering, and maximize the number of benefiting patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据